Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)

Costantino Romagnoli, Lina Bollani, Eugenio Baraldi, Gaetano Chirico, Andrea Dotta, Marcello Lanari, Antonello Del Vecchio, Paolo Manzoni, Antonio Boldrini, Piermichele Paolillo, Sandra Di Fabio, Luigi Orfeo, Mauro Stronati

Risultato della ricerca: Contributo in rivistaArticolo in rivista

43 Citazioni (Scopus)


Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease.Prevention of bronchiolitis strongly relies on the adoption of environment and the hygienic behavior measures; an additional prophylactic effect may be offered, in selected cases, by Palivizumab, a humanized monoclonal antibody produced by recombinant DNA technology, able to prevent RSV infection by blocking viral replication.After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection.
Lingua originaleEnglish
pagine (da-a)97-97
Numero di pagine1
Stato di pubblicazionePubblicato - 2015


  • RSV

Fingerprint Entra nei temi di ricerca di 'Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)'. Insieme formano una fingerprint unica.

Cita questo